Sorry, you need to enable JavaScript to visit this website.
移至主內容

The asia-pacific cro

Voted TOP10  GLOBAL CRO by WCG CenterWatch 2021 Global CRO Site Relationship Benchmark Survey of 3700 health care professionals worldwide.

Take advantage of the world's fastest growing clinical trials region.

Covid-19 Bulletins - CEO Update
Read More

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
CT -  Taipei City
CT -  Taipei City
TH -  Bangkok
NZ -  New Zealand
KR -  Seoul (Gangnam)
KR -  Gyeonggi-do
KR -  Seoul City Airport

North America

US -  Boston
US -  South Carolina

GLOBAL

English

CAREERS

SOLUTIONS

RESOURCES

ABOUT US

Location Settings

Asia-Pacific

AU -  Sydney
AU -  Melbourne
AU -  Brisbane
CN -  Hong Kong
CN -  Shanghai
IN -  Bangalore
MY -  Kuala Lumpur
PH -  Metro Manila
CT -  Taipei City
CT -  Taipei City
TH -  Bangkok
NZ -  New Zealand
KR -  Seoul (Gangnam)
KR -  Gyeonggi-do
KR -  Seoul City Airport

North America

US -  Boston
US -  South Carolina

GLOBAL

English

縮短試驗地點選擇與患者招募時間,加快臨床試驗

挑戰

歐洲和北美洲的試驗委託者,在招募和留住參加者、冗長時程和高昂成本等方面,面臨日益嚴峻的挑戰。亞太地區已成為臨床試驗的重點區域,主因在於本區具有龐大的患者人口、醫療設施的規模、政府支持臨床試驗、亞洲經濟體在終端消費者市場的策略重要地位、較低的試驗成本,以及高規格標準。

A multi-award winning regional contract research organization (CRO)

2021-best-practices-award
2021 CRO Leadership Award
2020 Asia Pacific Biotech CRO Company of the year (Frost & Sullivan)

Covid-19 Bulletins - CEO Update
Read More

Solutions we offer

Where We operate

  • Asia-Pacific
  • North America
Australia

Australia

  • High quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund
Greater China

Greater China

  • Very large, homogenous population
  • Strong focus of NMPA (previously CFDA) on shortening regulatory timelines
  • Largest clinical trial hub in Asia, with over 17,000 active investigators 
     
India

India

  • Large treatment-naïve population
  • High disease population load
  • The clinical activity grew by over 40% in 2018 on the back of regulatory pathway improvements
  • About 1,800 investigators have participated on a minimum of 5 studies
Malaysia

Malaysia

  • Multiethnic Asian population
  • Streamlined regulatory system and Strong govt. support 
  • Quick start-up timelines
  • Low patient costs and IRB fees
Philippines

Philippines

  • Large treatment-naïve population
  • Low costs
  • Overall good level of English
Singapore

Singapore

  • Multiethnic Asian population 
  • Regional clinical research hub
  • Efficient regulatory process and good infrastructure
South Korea

South Korea

  • Homogenous and concentrated population 
  • High quality medical services and excellent infrastructure
  • The most active Asian country in clinical research after China, with over 400 sites opened by biopharmas companies in 2018
Thailand

Thailand

  • Large homogenous population 
  • High prevalence of communicable diseases
  • Efficient regulatory system
  • Low operational cost
United States of America

United States of America

As part of a service expansion program, Novotech has acquired US CRO NCGS, a full service CRO managing clinical trials since 1984 and can now offer CRO services to biotech clients in the US to support early and late phase global studies.

New Zealand

New Zealand

  • High-quality research, facilities and equipment
  • Fast set-up and approval times
  • Sponsor can claim R&D cash refund

我們公司

「Novotech 是發展職涯的絕佳企業。我們非常看重為公司全體同仁提供令人願意投入的工作,經營包容共融的文化、彈性的工作場所,以及超高透明的溝通方式。我全力支持 Novotech 成為實施性別平等的領先業者,這也是我們公司的重要職場理念。」

- Dr. John Moller

Novotech CRO 執行長